E-LIB Suche - Ergebnisse für: Langley, Richard G

1

551 - Continuous tralokinumab treatment over 4 years in adu..:

Blauvelt, Andrew ; Langley, Richard G ; Peris, Ketty...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii48-ii49 , 2024

Link: https://doi.org/10.1093/..

2

555 - Safety of tralokinumab for the treatment of atopic de..:

Reich, Kristian ; Langley, Richard G ; Silvestre, Juan Francisco...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii52-ii53 , 2024

Link: https://doi.org/10.1093/..

3

Residual Lesional Gene Expression in Psoriasis Patients wit..:

Blauvelt, Andrew ; Gordon, Kenneth B. ; Langley, Richard G....
Journal of Investigative Dermatology. , 2024

Link: https://doi.org/10.1016/..

4

Guselkumab Reduces Disease- and Mechanism-Related Biomarker..:

Blauvelt, Andrew ; Langley, Richard G. ; Branigan, Patrick J....
JID Innovations. 4 (2024) 5 - p. 100287 , 2024

Link: https://doi.org/10.1016/..

5

Matching-adjusted indirect comparison of guselkumab versus ..:

Langley, Richard G. ; Sanyal, Chiranjeev ; Situ, Aaron...
JAAD International. 15 (2024) - p. 165-167 , 2024

Link: https://doi.org/10.1016/..

6

Rapid and sustained improvements in itch and quality of lif..:

Magnolo, Nina ; Cameron, Michael C. ; Shahriari, Mona...
Journal of Dermatological Treatment. 35 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

7

Differential Pharmacodynamic Effects on Psoriatic biomarker..:

Blauvelt, Andrew ; Chen, Yanqing ; Branigan, Patrick J....
JID Innovations. , 2024

Link: https://doi.org/10.1016/..

8

Orismilast in moderate-to-severe psoriasis: Efficacy and sa..:

Warren, Richard B. ; French, Lars E. ; Blauvelt, Andrew...
Journal of the American Academy of Dermatology. 90 (2024) 3 - p. 494-503 , 2024

Link: https://doi.org/10.1016/..

9

Effectiveness and safety of secukinumab updosing in patient..:

Papp, Kim A. ; Gooderham, Melinda ; Lynde, Charles...
Archives of Dermatological Research. 316 (2024) 7 - p. , 2024

Link: https://doi.org/10.1007/..

10

44134 Long-Term Improvement in Difficult-To-Treat Areas and..:

Elewski, Boni ; Rich, Phoebe ; Langley, Richard G....
Journal of the American Academy of Dermatology. 89 (2023) 3 - p. AB190 , 2023

Link: https://doi.org/10.1016/..

11

Secukinumab versus guselkumab in the complete resolution of..:

Krueger, James ; Langley, Richard G. ; Nigen, Simon...
Experimental Dermatology. 32 (2023) 10 - p. 1834-1847 , 2023

Link: https://doi.org/10.1111/..

12

Safety of guselkumab treatment for up to 5 years in patient..:

Lebwohl, Mark G ; Merola, Joseph F ; Rowland, Katelyn...
British Journal of Dermatology. 189 (2023) 1 - p. 42-52 , 2023

Link: https://doi.org/10.1093/..

13

Bimekizumab maintenance of response through 3 years in pati..:

Strober, Bruce ; Tada, Yayoi ; Mrowietz, Ulrich...
British Journal of Dermatology. 188 (2023) 6 - p. 749-759 , 2023

Link: https://doi.org/10.1093/..

14

Next Generation PDE4 Inhibitors that Selectively Target PDE..:

Blauvelt, Andrew ; Langley, Richard G. ; Gordon, Kenneth B....
Dermatology and Therapy. 13 (2023) 12 - p. 3031-3042 , 2023

Link: https://doi.org/10.1007/..

15

42664 Itching in patients with moderate to severe plaque ps..:

Augustin, Matthias ; Langley, Richard G. ; Warren, Richard B....
Journal of the American Academy of Dermatology. 89 (2023) 3 - p. AB184 , 2023

Link: https://doi.org/10.1016/..